Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Deferred Investment Award Programme.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications rather than financial performance data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details increases in notional interests in Ordinary Shares for specific individuals following the re-investment of dividends paid on April 10, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: April 15, 2014.
- Share Price: 1585.00 pence per Share.
- Event: Re-investment of dividends paid on April 10, 2014.
- Individuals Notified: Mr J Ford, Mr S A Hussain, Ms E Walmsley, and Mrs V A Whyte.
- Share Increases: 58.204, 201.180, 818.038, and 216.964 shares respectively.